Search Medical Condition
Please enter condition
Please choose location from dropdown

DeBary, Florida Clinical Trials

A listing of DeBary, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (113) clinical trials

Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer

OBJECTIVES: - To develop a web-based Breast Cancer Collaborative Registry (BCCR) as a repository for socio-demographic, environmental, clinical history, family history, and biospecimen data collected at the National Comprehensive Cancer Network (NCCN) centers for participants with a personal history of breast cancer and/or characteristics of hereditary breast cancer. - To ...

Phase N/A

4.22 miles

Learn More »

A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

This is a Phase 1/2, open-label, multicenter, sequential dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-e4 administered orally in subjects with advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations who have progressed while on treatment with an EGFR tyrosine kinase inhibitor (TKI) ...

Phase

4.22 miles

Learn More »

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH

Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria

Phase

4.22 miles

Learn More »

Study of Durvalumab + Tremelimumab Durvalumab and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Phase

4.22 miles

Learn More »

An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have RRMM. This study will compare the efficacy and safety in participants who take ixazomib and dexamethasone to pomalidomide and dexamethasone. It is an open-label, phase 2 study that, on the basis ...

Phase

4.22 miles

Learn More »

A phase III Efficacy and Safety of 3 week fixed dose asenapin treatment in pediatric acute manic or mixed episodes associated with Bipolar 1 Disorder in adolescents. Patient Inclustion Criteria: The subject is aged between 10 and 17 years, inclusive. The subject suffers from bipolar 1 disorder.

Phase

4.22 miles

Learn More »

An 8 week, placebo-controlled, double-blind, randomized, fixed-dose efficacy and safety study of asenapine in adolescent subjects with schizophrenia. Patient Inclustion Criteria: The subject is aged between 10 and 17 years, inclusive. The subject suffers from schizophrenia.

Phase

4.22 miles

Learn More »

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects Patient Inclustion Criteria: The subject is a man or woman ...

Phase

4.22 miles

Learn More »

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar 1 Disorder in Adult Subjects. Patient ...

Phase

4.22 miles

Learn More »

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+ HER2- Advanced Breast Cancer

QT interval prolongation and neutropenia are considered to be important identified risks for ribociclib (Kisqali Prescribing Information, Investigator Brochure). The approved dosing regimen of ribociclib is 600 mg daily (QD) on a 3 weeks on/1 week off schedule. The purpose of the study is to explore whether a reduced dosing ...

Phase

4.22 miles

Learn More »